Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...

Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Laboratories stock falls after earnings even as the company reports second-quarter sales that top expectations.

Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, ...

Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories closed 14.67% below its 52-week high of $141.23, which the company achieved on March 4th.

The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.

Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q2 CY2025, with sales up 7.4% year on year to $11.14 ...